Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 300 results for breast cancer

  1. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

  2. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

  3. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

  4. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

  5. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

  6. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

  7. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

  8. Microwave ablation for primary or metastatic cancer in the lung (IPG716)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

  9. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

  10. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

  11. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued [GID-TA11178]

  12. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  13. AlignRT for intracranial stereotactic radiosurgery (MIB147)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .